Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ispinesib in Non-Small Cell Lung Cancer
NCT00085813Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2003
- Primary completion
- Oct 2005
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of ispinesib in non-small cell lung cancer (NSCLC), sponsored by GSK. Primary endpoint: Overall Response Rate. Started Dec 2003; status: completed.
02
Drugs
ispinesib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00085813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00085813.